Metronomic Chemotherapy in Wilms Tumor (MetroWilms-1906)

This is a multicenter, interventional, non-randomized study among patients with a relapsed or refractory Wilms tumor. The study will aim to assess efficacy of metronomic chemotherapy, in terms of disease control after two cycles of metronomic chemotherapy.

Trial Details

NCT ID
NCT05384821
Phase
PHASE1 / PHASE2
Sponsor
Centre Oscar Lambret
Status
RECRUITING
Cancer Type
Kidney Cancer
Interventions
  • Vincristine
  • Irinotecan
  • Temozolomide
  • Etoposide
  • Cis-Retinoic acid
Locations (sample)
  • Amiens, France|49.9,2.3
  • Besançon, France|47.24878,6.01815
  • Bordeaux, France|44.84124,-0.58046
  • Grenoble, France|45.17869,5.71479
  • Lille, France|50.63391,3.05512

Key Eligibility Criteria

  • Patient ≥18 months old and ≤ 17 years old
  • Relapsed or refractory Wilms tumor, histologically proven at diagnosis
  • After at least 2 lines of chemotherapy (conventional or high dose, which may include the trial molecules) or after 1 line for high risk relapse for…
  • Radiologically measurable or evaluable disease (visible, target or non-target-lesion on MRI or CT-scan)

For full eligibility, visit ClinicalTrials.gov.

Check If You May Be Eligible

Trialify translates complex eligibility criteria into plain yes-or-no questions to help you understand if this trial might be right for you.

Find Kidney Cancer Trials on Trialify →